CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $82.00

CRISPR Therapeutics (NASDAQ:CRSP) had its target price boosted by Needham & Company LLC from $80.00 to $82.00 in a research note released on Friday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Royal Bank Of Canada raised their target price on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 11th. Citigroup restated a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Friday, January 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st. Chardan Capital dropped their price target on CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating on the stock in a research note on Wednesday, November 26th. Finally, Robert W. Baird cut their price target on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Eleven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $67.35.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $53.07 on Friday. The company has a market cap of $5.09 billion, a price-to-earnings ratio of -8.14 and a beta of 1.72. The firm has a 50-day moving average of $54.22 and a 200-day moving average of $57.35. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. During the same period last year, the company posted ($1.01) earnings per share. The business’s revenue for the quarter was down 97.8% on a year-over-year basis. As a group, sell-side analysts expect that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total value of $3,613,800.00. Following the transaction, the chief executive officer directly owned 134,201 shares in the company, valued at approximately $8,082,926.23. This represents a 30.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CRSP. Mirae Asset Global Investments Co. Ltd. raised its position in shares of CRISPR Therapeutics by 5.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after buying an additional 180 shares in the last quarter. IFP Advisors Inc raised its holdings in CRISPR Therapeutics by 24.6% in the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after acquiring an additional 181 shares in the last quarter. Cerity Partners LLC raised its holdings in CRISPR Therapeutics by 3.0% in the 2nd quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after acquiring an additional 190 shares in the last quarter. Peapack Gladstone Financial Corp lifted its position in shares of CRISPR Therapeutics by 3.0% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock valued at $339,000 after acquiring an additional 200 shares during the period. Finally, Optiver Holding B.V. grew its holdings in shares of CRISPR Therapeutics by 71.4% during the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after purchasing an additional 210 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Key Headlines Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Casgevy commercial momentum—management highlighted that Casgevy generated about $54M in Q4 and $116M for full‑year 2025, supporting the view that adoption for the company’s approved SCD/TDT therapy is expanding and producing meaningful sales. CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
• Positive Sentiment: Analyst upgrade/price‑target lift—Needham raised its price target to $82 and maintained a Buy rating, signaling institutional conviction that shares have upside on continued commercial execution. CRSP Price Target Raised by Needham
• Neutral Sentiment: Official business update and results—CRISPR published its Q4 and full‑year 2025 results and a business update emphasizing pipeline progress and upcoming label expansion plans; this is informative for longer‑term thesis but contains limited near‑term financial guidance. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Positive retail narrative—an upbeat Fool feature framed the company as a “blastoff‑ready” biotech pick for 2026, which can boost retail buying interest but is opinion‑driven. The Blastoff-Ready Biotech Stock You’ll Kick Yourself for Not Buying in 2026
• Neutral Sentiment: Short‑interest data appears anomalous—recent reports show short interest listed as 0 shares (likely a reporting/data issue), so short‑interest signaling is unclear and should be treated cautiously.
• Negative Sentiment: Quarterly miss and wider loss—CRSP reported Q4 EPS of ($1.37) versus consensus ($1.15) and revenue of $0.86M versus $4.72M expected; revenue fell sharply year‑over‑year, underscoring near‑term financial pressure and a negative margin/earnings backdrop. CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.